This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Singh, H. Articles by Cooper, L. J.N. Search for Related Content PubMed PubMed Citation Articles by Singh, H. Articles by Cooper, L. J.N.

Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System

Divisions of ¹ Pediatrics and ² Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas; ³ Department of Genetics, Cell Biology and Development, University of Minnesota, St. Paul, Minnesota; and ⁴ Division of Research Immunology/Bone Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, California

Requests for reprints: Laurence J.N. Cooper, University of Texas M. D. Anderson Cancer Center, Pediatrics-Research, Unit 907, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-563-3208; Fax: 713-792-9832; E-mail: ljncooper{at}mdanderson.org.

Key Words: CD19 • memory cells • effector cells • T cells • Sleeping Beauty • gene transfer

Genetic modification of clinical-grade T cells is undertaken to augment function, including redirecting specificity for desired antigen. We and others have introduced a chimeric antigen receptor (CAR) to enable T cells to recognize lineage-specific tumor antigen, such as CD19, and early-phase human trials are currently assessing safety and feasibility. However, a significant barrier to next-generation clinical studies is developing a suitable CAR expression vector capable of genetically modifying a broad population of T cells. Transduction of T cells is relatively efficient but it requires specialized manufacture of expensive clinical grade recombinant virus. Electrotransfer of naked DNA plasmid offers a cost-effective alternative approach, but the inefficiency of transgene integration mandates ex vivo selection under cytocidal concentrations of drug to enforce expression of selection genes to achieve clinically meaningful numbers of CAR⁺ T cells. We report a new approach to efficiently generating T cells with redirected specificity, introducing DNA plasmids from the Sleeping Beauty transposon/transposase system to directly express a CD19-specific CAR in memory and effector T cells without drug selection. When coupled with numerical expansion on CD19⁺ artificial antigen-presenting cells, this gene transfer method results in rapid outgrowth of CD4⁺ and CD8⁺ T cells expressing CAR to redirect specificity for CD19⁺ tumor cells. [Cancer Res 2008;68(8):2961–71]

This article has been cited by other articles:

				T. VandenDriessche, Z. Ivics, Z. Izsvak, and M. K. L. Chuah Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells Blood, August 20, 2009; 114(8): 1461 - 1468. [Abstract] [Full Text] [PDF]

				X. Xue, X. Huang, S. E. Nodland, L. Mates, L. Ma, Z. Izsvak, Z. Ivics, T. W. LeBien, R. S. McIvor, J. E. Wagner, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system Blood, August 13, 2009; 114(7): 1319 - 1330. [Abstract] [Full Text] [PDF]

				L. J.N. Cooper Persuading Natural Killer Cells to Eliminate Bad B Cells Clin. Cancer Res., August 1, 2009; 15(15): 4790 - 4791. [Abstract] [Full Text] [PDF]